IL-1 receptor antagonist as an aerosol in inflammation

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 20, Issue 4, 2007, Pages 445-459

  Ischenko, Alexander M ^a   Nikolaev, Boris P ^a   Kotova, Tatiana V ^a   Vorobeychikov, Eugeny V ^a   Konusova, Velentina G ^a   Yakovleva, Ludmila Y ^a  

^a Institute for Highly Pure Biopreparations   (Russian Federation)

Author keywords

Aerosol; Dry powder; Human IL 1 receptor antagonist; IL 1Ra; Inflammation; Intranasal lipopolysaccharide

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LACTIC ACID; LUMINOL; PROTEIN; REACTIVE OXYGEN METABOLITE;

AERATION; AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRY POWDER; ELECTROCHEMISTRY; LUNG LAVAGE; MATHEMATICAL MODEL; MICRONIZED POWDER; MICROSCOPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION POTENTIAL; PARTICLE SIZE; PH; PNEUMONIA; POWDER;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MICE; MICE, INBRED C57BL;

EID: 37549021073     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/jam.2007.0576     Document Type: Article

References (40)

1. Ohlsson, K., P. Bjork, M. Bergenfeldt, R. Hageman, and R.C. Thompson. 1990. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348:550-552.
2. Ulich, T.R., S. Yin, K. Guo, J. del Castillo, S.P. Eisenberg, and R.C. Thompson. 1991. The intratracheal administration of endotoxin and cytokines.III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. Am. J. Pathol. 138:521-524.
3. Danilov, L.N., E.C. Lebedeva, I.V. Dvorakovskay, A.S. Simbirtsev, and M.M. Ilkovich. 2003. Effect of receptor antagonist IL-1Ra on the development of oxidative stress in lung. Cytokine Inflamm 2:14-20 (in Russian).
4. Selig, W., and J. Tocker. 1992. Effect of interleukin-1 receptor antagonist on antigen-induced pulmonary responses in guinea pig. Eur. J. Pharmacol. 213:331-336.
5. Sun, D., M. Zhao, D. Ma, S. Liao, and C. Di. 1996. Protective effect of interleukin-1 receptor antagonist on oleic acid-induced lung injury. Chin. Med. J. 109:522-526.
6. Chang, D.-M., S.-Y. Chang, M.-K. Yeh, and J.-H. Lai. 2004. The pharmacokinetics of interleukin-1 receptor antagonist in Chinese subjects with rheumatoid arthritis. Pharmacol. Res. 50:371-376.
7. Donaldson, K., and C.L. Tran. 2002. Inflammation caused by particles and fibers. Inhalat. Toxicol. 14:5-27.
8. Folkesson, H.G., L. Hedin, and B.R. Westrom. 1992. Lung to blood passage of human growth hormone from the rat lung. J. Endocrinol. 134:197-203.
9. Colthorpe, P., S.J. Farr, I.J. Smith, D. Wyatt, and G. Taylor. 1995. The influence of regional deposition on the pharmacokinetics of pulmonary delivered human growth hormone in rabbits. Pharm. Res. 12:356-359.
10. Bosquillon, C., V Preat, and R Vanbever. 2004. Pulmonary delivery of growth hormone using dry powders and visualization of its pulmonary fate. J. Control. Release 96:233-244.
11. Codrons, V., F. Vanderbist, B. Ucakar, V. Preat, and R. Vanbever. 2004. Impact of formulation and methods of pulmonary administration on absorption of parathyroid hormone (1-34) from rat lungs. J. Pharm. Sci. 93:1241-1252.
12. Patton, J.S., J. Bukar, and S. Nagarajan. 1999. Inhaled insulin. Adv. Drug Deliv. Rev. 35:235-247.
13. Eljamal, M., and J.S. Patton. 1998. Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin. Patent USA. No. 5780014.
14. Chan, H.K., A. Clark, I. Gonda, M. Mumenthaler, and C. Hsu. 1997. Spray dried powders and powder blends of recombinant human deoxyribonuclease (rhDNase) for aerosol delivery. Pharm. Res. 14:431-437.
15. Bosquillon, C., C. Lombry, V. Preat, and R. Vanbever. 2001. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J.Control. Release 70:329-339
16. Agu, R.U., M.I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke. 2001. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2:198-209.
17. Smith, P.L. 1997. Peptide delivery via the pulmonary route: a valid approach for local and systemic delivery. J. Control. Release 46:99-106.
18. Heyder, J., J. Gebhart, G. Rudolf, C.F. Schiller, and W. Stahlhofen. 1986. Deposition of particles in the human respiratory tract in the size range 0.005-15. Am. J. Aerosol Sci. 17:811-825.
19. Ferin, J, G. Oberdoerster, and D.P. Penney. 1992. Pulmonary retention of ultrafine and fine particles in rats. Am. J. Respir. Cell Mol. Biol. 6:535-542.
20. Schulz, H. 1998. Mechanisms and factors affecting intrapulmonary particle deposition: implications for efficient inhalation therapies. Pharm. Sci. Technol. Today 1:336-344.
21. Niven, R. 1997. Dry powder formulations for inhalation. Adv. Drug Deliv. Rev. 26:1-67.
22. Kim, K.J., and A.B. Malik. 2003. Protein transport across the lung epithelial barrier. Am. J. Physiol., Lung Cell Physiol. 284:L247-L259.
23. Hickey, A.J., N.M. Concessio, M.M. Van Oort, and R.M. Platz. 1994. Factors influencing the dispersion of dry powders as aerosols. Pharm. Technol. 18:58-64.
24. Prime, D., P.J. Atkins, A. Slater, and B. Sumby. 1997. Review of dry powder inhalers. Adv. Drug Deliv. Rev. 26:51-58.
25. Savov, J.D., S.H. Gavett, D. M. Brass, D. Costa, D. A. Schwartz. 2002. Neutrophils play a critical role in development of LPS-induced airway disease. Am. J. Physiol. Lung Cell Mol.Physiol. 283:952-962.
26. Gapochko, K.G., O.P. Misnikov, V.I. Moskalenko. 1986. Analysis of errors in determining the aspiration dosage in aerosol immunization and in the experimental study of aerogenic infections. Zh. Mikrobiol. Epidemiol. Immunobiol. 8:45-48 (in Russian).
27. Chap, T. Le. 2003. Introductory Biostatistics. John Wiley & Sons. Inc., Hobokon, NJ, 551.
28. Illum, L. 2003. Nasal drug delivery - possibilities, problems and solutions. J. Control. Release 67:187-198.
29. Lombry, C., D.A. Edwards, V. Preat, and R. Vanbever. 2004. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. Am. J. Physiol. Lung Cell Physiol. 286:L1002-L1008.
30. Tobin, M.J. 2002. Asthma. Airway biology and nasal disordres in AJRCCM. Am. J. Respir. Crit. Careed. 165: 598-618.
31. Park, J.-W., C. Taube, C. Swasey, T. Kodama, A. Joetham, A. Balhorn, K. Takeda, N. Miyahara, C.B. Allen, A. Dakhama, S.-H. Kim, C.A. Dinarello, and E.W. Gelfand. 2004. Interleukin-1 receptor antagonist attenuates airway hyperresponsiveness following exposure to ozone. Am. J. Resp. Cell Mol. Biol. 30:830-836.
32. Shanley, T.P., J.L. Peters, M.L. Jones, Chensue, S.L Kunkel, and P.A. Ward. 1996. Regulatory effects of endogenous interleukin-1 receptor antagonist protein in immunology G immune complex-induced lung injury. J. Clin. Invest. 97:963-970.
33. Wheeler, M.D., and R.G. Thurman. 1999. Production of superoxide and TNF-α from alveolar macrophages is blunted by glycine. Lung Cell. Mol. Physiol. 277: L952-L959.
34. Moreland, J.G., R.M. Fuhrman, C.L. Wohlford-Lenane, T.J. Quinn, E. Benda, J.A. Pruessner, and D.A. Schwartz. 2001. TNF-α and IL-1β are not essential to the inflammatory response in LPS-induced airway disease. AJP Lung Cell. Mol. Physiol. 280:L173-L180.
35. Wilmott, R.W., J.A. Kitzmiller, M.A. Fiedler, and J.M. Stark. 1998. Generation of a transgenic mouse with lung-specific overexpression of the human interleukine-1 receptor antagonist protein. Am. J. Respir. Cell Mol. Biol. 18:429-434.
36. Debs, R.J., H.J. Fuchs, R. Philip, A.B. Montgomery, E.N. Brunette, D. Liggitt, J.S. Patton, and J.E. Shellito. 1988. Lung-specific delivery of cytokines induced sustained pulmonary and systemic immunomodulation in rats. J. Immunol. 140:3482-3488.
37. Victor, V.M., M. Rocha, and M. De la Fuente. 2004. Immune cells: free radicals and antioxidants in sepsis. Internat. Immunopharmacol. 4:327-347.
38. Larsen, G.L., and P.G. Holt. 2000. The concept of airway inflammation. Am. J. Crit. Care Med. 162:S2-S6.
39. Miller, D.L, K. Welty-Wolf, M. Carraway, M. Ezban, A. Ghio, H. Suliman, and C.A. Piantadosi. 2002. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am. J. Respir. Cell Mol. Biol. 26(6):650-658.
40. Strieter, R.M., S.L. Kunkel, M.P. Keane, and T.J. Standiford. 1999. Chemokines in lung injury. Chest 116: 103S-110S.